Blueprint Medicines Corporation (NASDAQ: BPMC) todavía reporta financiales desenlaces y provee a business update for the second cuartel ended June 30, 2022.
(SM) y prosigue taburete a significante expansión de nuestra prescribe base a su eventual demanda, reinforcing su convisión a su opportunity en SM,” said Kate Haviland, Chief Executive Officer of Blueprint Medicines. “We track to announce topline data from la registration-enabling PIONEER trial en Augusto, el que catalyze la ability to bring AYVAKIT’s transformative potencial en sufrientes living with non-advanced SM. Inadición, we prosigue to make significando progresos sobre la pipeline de originales indagaciones medicinas en EGFR-mutant y CDK2-vulnerable cancers. We look forward sharing more sobre su strategic visión, incluyendo las opciones we see in SM, EGFR-mutant lung cancer, and CDK2-vulnerable cancers, y nuestro expanding research platform will continue to drive innovation at Investor Day on Novem 2022 a New York, NY. Con su enorme revenue performance, en la clínica-stage pipeline of five significando asets, y well over $1 billion in cash en su cómputo sheet as de toda, we uniquely positioned to drive near- and long-term value para all of our stakeholder delivering transformative precision medicinas to sufrientes around the world.”
Meet us con AMP 2022
November 1-5, 2022 en Phoenix, Arizona
#906. La combinación de artificial sabiduría y human expertise, la AMI es un único propio con QIAGEN. AMI usas machines to rapidly index millions of articles. Then, humano curators review y certify the accuracy, importancia, and consistency of the information pulled.
Official comments
Lea author, Dr. Robert Pitceathly, coleado por el London NHS “The NHS ha ungido heavily in advanced genetic technologies. Consecuentemente, el UK ha predeterminado itself en el forefront of diagnostic whole genome sequencing. Este said, somos people with rare genetico diseños remain without a molecular diagnosis after their genome is analysed.
“Está bien investigado en los expertos genómico médicos y es vital, ofreciendo equitable ingreso a aplicados multidisciplinares expertise and maximising diagnoses. Average, pacientes en su estudio waited over 30 years for diagnosis – no hay aptitud para arreglar sus casos pero precisan correctas workforce planning para el soporte NHS diagnostic genetic laboratorios in achieving this goal.”
Relacionado:
emory university school of medicine’s internal review board irb
use of alternative medicine for cancerand its impact on survival
